SCHEMBL1971506

SCHEMBL1971506

O=[N+]([O-])c1cccc(S(=O)(=O)n2ccc3ccccc32)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 2/20 0.66
KMT2A Q03164 6/20 0.61
HTT P42858 4/20 0.61
MEN1 O00255 4/20 0.61
HTR6 P50406 3/20 0.61
LMNA P02545 2/20 0.61
ALDH1A1 P00352 2/20 0.61
HPGD P15428 1/20 0.61
TSHR P16473 1/20 0.61
PKM P14618 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
GAA P10253 1/20 0.53
MAPT P10636 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
RAPGEF4 Q8WZA2 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
HDAC3 O15379 1/20 0.50
HDAC4 P56524 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC7 Q8WUI4 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30041274 0.86 HTR6 (0.69) METKMT2AHTTMEN1HTR6
SCHEMBL1395018 0.86 HTR6 (0.69) METKMT2AHTTMEN1HTR6
SCHEMBL20742991 0.82 HTR6 (0.62) METKMT2AHTTMEN1HTR6
SCHEMBL2512172 0.82 HTR6 (0.62) METKMT2AHTTMEN1HTR6
SCHEMBL6236469 0.80 MET (0.52) METKMT2AHTTMEN1HTR6
SCHEMBL3972209 0.78 HTR6 (0.70) KMT2AHTTMEN1HTR6LMNA
SCHEMBL29558135 0.77 HTR6 (1.00) METKMT2AHTTMEN1HTR6
SCHEMBL429849 0.77 HTR6 (1.00) METKMT2AHTTMEN1HTR6
SCHEMBL1974915 0.77 HTR6 (0.70) METKMT2AHTTMEN1HTR6
SCHEMBL1973635 0.77 HTR6 (0.69) KMT2AHTTMEN1HTR6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003670-B2 Aminoalkoxy aryl sulfonamide compounds and their use as 5-HT6 ligands SUVEN LIFE SCIENCES LIMITED (IN) 2011-08-23 US disclosed
US-7998981-B2 Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands SUVEN LIFE SCIENCES LIMITED (IN) 2011-08-16 US disclosed
EP-2155674-B1 AMINOALKOXY ARYL SULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LTD (IN) 2011-06-22 EP disclosed
US-20100168168-A1 Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands SUVEN LIFE SCIENCES, LTD. (IN) 2010-07-01 US disclosed
US-20100087484-A1 AMINOALKOXY ARYL SULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2010-04-08 US disclosed
EP-2155674-A1 AMINOALKOXY ARYL SULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS Suven Life Sciences Limited (IN) 2010-02-24 EP disclosed
EP-1919896-B1 AMINOARYL SULPHONAMIDE DERIVATIVES AS FUNCTIONAL 5-HT6 LIGANDS. SUVEN LIFE SCIENCES LTD (IN) 2009-12-23 EP disclosed
WO-2008136017-A1 AMINOALKOXY ARYL SULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2008-11-13 WO disclosed
EP-1919896-A1 AMINOARYL SULPHONAMIDE DERIVATIVES AS FUNCTIONAL 5-HT6 LIGANDS. Suven Life Sciences Limited (IN) 2008-05-14 EP disclosed
WO-2007020652-A1 AMINOARYL SULPHONAMIDE DERIVATIVES AS FUNCTIONAL 5-HT6 LIGANDS. SUVEN LIFE SCIENCES LIMITED (IN) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168168-A1 Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands HTR6, HTR5A, HTR3B MET 600/4885KMT2A 1675/4885HTT 492/4885
US-20100087484-A1 AMINOALKOXY ARYL SULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS HTR6, HTR5A, HTR1B MET 974/4885KMT2A 1240/4885HTT 636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.